HYPMY Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of 20.38% compared to Hypera SA's net margin of -116.82%. Hypera SA's return on equity of 6.9% beat Agenus, Inc.'s return on equity of --.

Hypera SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 267.06%. Given that Agenus, Inc. has higher upside potential than Hypera SA, analysts believe Agenus, Inc. is more attractive than Hypera SA.

Hypera SA has a beta of 0.712, which suggesting that the stock is 28.827% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.

Hypera SA has a quarterly dividend of $0.05 per share corresponding to a yield of 4.75%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hypera SA pays 36.44% of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend. Hypera SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hypera SA quarterly revenues are $408.8M, which are larger than Agenus, Inc. quarterly revenues of $30.2M. Hypera SA's net income of $83.3M is higher than Agenus, Inc.'s net income of $63.9M. Notably, Hypera SA's price-to-earnings ratio is 19.53x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypera SA is 2.35x versus 0.85x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of 20.38% compared to Hypera SA's net margin of 16.99%. Hypera SA's return on equity of 6.9% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Hypera SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.97%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Hypera SA, analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Hypera SA.

Hypera SA has a beta of 0.712, which suggesting that the stock is 28.827% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Hypera SA has a quarterly dividend of $0.05 per share corresponding to a yield of 4.75%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hypera SA pays 36.44% of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Hypera SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hypera SA quarterly revenues are $408.8M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Hypera SA's net income of $83.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Hypera SA's price-to-earnings ratio is 19.53x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 146.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypera SA is 2.35x versus 11.91x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Raia Drogasil SA has a net margin of 20.38% compared to Hypera SA's net margin of 4.1%. Hypera SA's return on equity of 6.9% beat Raia Drogasil SA's return on equity of 20.46%.

Hypera SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Raia Drogasil SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Hypera SA has higher upside potential than Raia Drogasil SA, analysts believe Hypera SA is more attractive than Raia Drogasil SA.

Hypera SA has a beta of 0.712, which suggesting that the stock is 28.827% less volatile than S&P 500. In comparison Raia Drogasil SA has a beta of -0.066, suggesting its less volatile than the S&P 500 by 106.573%.

Hypera SA has a quarterly dividend of $0.05 per share corresponding to a yield of 4.75%. Raia Drogasil SA offers a yield of 0.57% to investors and pays a quarterly dividend of $0.03 per share. Hypera SA pays 36.44% of its earnings as a dividend. Raia Drogasil SA pays out 34.22% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Hypera SA quarterly revenues are $408.8M, which are smaller than Raia Drogasil SA quarterly revenues of $2.1B. Hypera SA's net income of $83.3M is lower than Raia Drogasil SA's net income of $84.7M. Notably, Hypera SA's price-to-earnings ratio is 19.53x while Raia Drogasil SA's PE ratio is 37.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypera SA is 2.35x versus 1.18x for Raia Drogasil SA. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of 20.38% compared to Hypera SA's net margin of --. Hypera SA's return on equity of 6.9% beat Savara, Inc.'s return on equity of -78.83%.

Hypera SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 81.11%. Given that Savara, Inc. has higher upside potential than Hypera SA, analysts believe Savara, Inc. is more attractive than Hypera SA.

Hypera SA has a beta of 0.712, which suggesting that the stock is 28.827% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

Hypera SA has a quarterly dividend of $0.05 per share corresponding to a yield of 4.75%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hypera SA pays 36.44% of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend. Hypera SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hypera SA quarterly revenues are $408.8M, which are larger than Savara, Inc. quarterly revenues of --. Hypera SA's net income of $83.3M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Hypera SA's price-to-earnings ratio is 19.53x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypera SA is 2.35x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.